EP 0576227 A3 19940209 -
Publication
Application
Priority
US 90230492 A 19920622
Abstract (en)
[origin: EP0576227A2] 2-Deoxy-2,2-Difluoro (2,6,8-Substituted) Purine Nucleosides Having Anti-Cancer and Anti-Viral Activity and Intermediates.
IPC 1-7
IPC 8 full level
A61K 31/70 (2006.01); A61K 31/7042 (2006.01); A61K 31/7052 (2006.01); A61K 31/7064 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); C07H 17/02 (2006.01); C07H 19/04 (2006.01); C07H 19/14 (2006.01); C07H 19/16 (2006.01); C07H 19/23 (2006.01)
CPC (source: EP KR)
A61K 31/7056 (2013.01 - KR); A61K 31/706 (2013.01 - KR); A61P 31/12 (2017.12 - EP); A61P 35/00 (2017.12 - EP); C07H 19/04 (2013.01 - EP); C07H 19/16 (2013.01 - EP KR)
Citation (search report)
- [X] EP 0328345 A2 19890816 - LILLY CO ELI [US]
- [XD] EP 0184365 A2 19860611 - LILLY CO ELI [US]
- [XD] EP 0329348 A2 19890823 - LILLY CO ELI [US]
- [XD] EP 0211354 A2 19870225 - MERRELL DOW PHARMA [US]
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE
DOCDB simple family (publication)
EP 0576227 A2 19931229; EP 0576227 A3 19940209; AU 4134793 A 19931223; BR 9302433 A 19940111; CA 2098876 A1 19931223; CN 1084178 A 19940323; CZ 123293 A3 19940316; FI 932868 A0 19930621; FI 932868 A 19931223; HU 9301821 D0 19930928; HU T64553 A 19940128; IL 106073 A0 19931020; JP H0656877 A 19940301; KR 940005656 A 19940322; MX 9303709 A 19940531; NO 932287 D0 19930621; NO 932287 L 19931223; PL 299412 A1 19931227
DOCDB simple family (application)
EP 93304815 A 19930621; AU 4134793 A 19930618; BR 9302433 A 19930621; CA 2098876 A 19930621; CN 93107740 A 19930621; CZ 123293 A 19930621; FI 932868 A 19930621; HU 9301821 A 19930621; IL 10607393 A 19930621; JP 14919193 A 19930621; KR 930011308 A 19930621; MX 9303709 A 19930621; NO 932287 A 19930621; PL 29941293 A 19930621